医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s Laboratories to Acquire Select Business Divisions of Wockhardt in India

2020年02月12日 PM04:56
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that it has entered into a definitive agreement with Wockhardt Limited to acquire select divisions of its branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives for a consideration of Rs.1850 Crores.

The business comprises of a portfolio of 62 brands in multiple therapy areas such as Respiratory, Neurology, VMS, Dermatology, Gastroenterology, Pain and Vaccines, which would transfer to Dr. Reddy’s along with related sales and marketing teams; and the manufacturing plant located in Baddi, Himachal Pradesh with all plant employees. The business undertaking is being transferred on a slump sale basis.

G V Prasad, the Co-Chairman and Managing Director of Dr. Reddy’s said, “India is an important market for us and this acquisition will help in considerably scaling-up our domestic business. The acquired portfolio shall enhance Dr. Reddy’s presence in the high growth therapy areas with market leading brands such as Practin, Zedex, Bro-zedex, Tryptomer and Biovac. We believe the portfolio holds a lot of potential and will get an impetus under Dr. Reddy’s. We welcome the team joining as part of the deal to the Dr. Reddy’s family.”

The transaction is expected to be closed in the first quarter of the financial year 2020-21.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200211006190/en/

CONTACT

INVESTOR RELATIONS

AMIT AGARWAL

amita@drreddys.com

(PH: +91-40-49002135)

MEDIA RELATIONS

DEEP GHATAK

deepghatak@drreddys.com

(PH: +91-40-49002121)

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 自治医科大学和CureApp, Inc.:首个Digital Therapeutics治疗高血压的3期临床试验在日本启动
  • UnitedHealth Group Commits Additional $10 Million for COVID-19 International Response
  • Sermo Reports: Zinc and Vitamins C and D Recommended By Global Physicians to Treat and Build Resistance to COVID-19
  • Hytera Actively Participates in the Fight Against COVID-19, Helping to Prevent Cross-infections
  • ReForm Biologics Announces the Issuance of U.S. and Japanese Patents for Therapeutic Protein Formulations